High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels
Chang JP, Su KP, Mondelli V, Satyanarayanan SK, Yang HT, Chiang YJ, Chen HT, Pariante CM
Translational psychiatry · 63 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- South London and Maudsley NHS Foundation Trust
- Gobierno
- National Institute for Health and Care Research
- Universidad u hospital
- King's College London
- Universidad u hospital
- China Medical University Hospital
- Gobierno
- Ministry of Science and Technology, Taiwan
- Gobierno
- National Health Research Institutes
- Universidad u hospital
- China Medical University
- Gobierno
- Medical Research Council
- Gobierno
- Division of Materials Research
- Gobierno
- National Institute for Health Research (NIHR)
- Subvenciones
- Ministry of Science and Technology, Taiwan (MOST107-2314-B039-005); National Health Research Institutes (DMR-107-091); South London and Maudsley NHS Foundation Trust (MR/L014815/1); National Health Research Institutes (DMR-108-216); Medical Research Council (MR/L014815/1); China Medical University Hospital (CRS-106-063); National Institute for Health and Care Research (NHRI-EX105-10528NI); National Health Research Institutes (CRS-108-048); National Institute for Health and Care Research (MR/J002739/1); National Health Research Institutes (CMU108-SR-106); China Medical University Hospital (DMR-107-202); Ministry of Science and Technology, Taiwan (105-2918-I-039-001;); National Health Research Institutes (DRM-108-091); Ministry of Science and Technology, Taiwan (104-2314-B-039-022-MY2,); National Institute for Health and Care Research (MR/L014815/1); National Health Research Institutes (NHRI-EX108-10528NI); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-035); China Medical University Hospital (DMR‐107‐204); National Institute for Health and Care Research (NIHR200256); China Medical University (CMU108‐SR‐106); South London and Maudsley NHS Foundation Trust (MR/J002739/1); National Health Research Institutes (NHRI-EX105-10528NI); China Medical University (CRS-108-048); National Health Research Institutes (CRS-106-063); National Health Research Institutes (DMR-107-204); National Health Research Institutes (CMU106-S-33); National Institute for Health and Care Research (NF-SI-0616-10074); Medical Research Council (MR/N029488/1); National Health Research Institutes (CRS-106-063, DMR-107-202); China Medical University (DMR‐108‐216); Medical Research Council (MR/J002739/1); Ministry of Science and Technology, Taiwan (MOST106-2314-B038-049); Ministry of Science and Technology, Taiwan (CMU108-SR-106); National Health Research Institutes (DRM-107-097); Ministry of Science and Technology, Taiwan (MOST 108-); Ministry of Science and Technology, Taiwan (MOST103-2923-B039-002-MY3); Ministry of Science and Technology, Taiwan (MOST108-2320-B039-048); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-027-MY3); Ministry of Science and Technology, Taiwan (MOST108-2314-B039-016); Ministry of Science and Technology, Taiwan (NHRI-EX108-10528NI); Ministry of Science and Technology, Taiwan (MOST104-2314-B039-050-MY3); Medical Research Council (MR/J002739/1); National Health Research Institutes (DMR-107-202); Ministry of Science and Technology, Taiwan (MOST103-2320-B039-036); Medical Research Council (MR/L014815/1); Ministry of Science and Technology, Taiwan (MOST106-2314-B039-031)
Según 10 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2019-11-20 · Transl Psychiatry · vol. 9 · número 1 · pág. 303
- Editorial
- Springer Nature
- Citado
- 88 citas · más que el 99% de estudios similares · 15.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Birth, Development, and Health · Diet and metabolism studies · Fatty Acid Research and Health
- Palabras clave
- Placebo, Eicosapentaenoic acid, Impulsivity, Attention deficit hyperactivity disorder, Polyunsaturated fatty acid, Vigilance (psychology), Internal medicine, Psychology, Medicine, Psychiatry, Fatty acid, Biochemistry, Chemistry
- MeSH
- humans, eicosapentaenoic acid, treatment outcome, double-blind method, cognition, attention, attention deficit disorder with hyperactivity, adolescent, child, taiwan, female, male
8 autores
- Jane Pei‐Chen Chang🇬🇧🇹🇼King's College London; China Medical University; China Medical University Hospital
- Kuan‐Pin Su🇬🇧🇹🇼 · autor de correspondenciaKing's College London; China Medical University; China Medical University Hospital
- Valeria Mondelli🇬🇧King's College London
- Senthil Kumaran Satyanarayanan🇹🇼China Medical University; China Medical University Hospital
- Hui-Ting Yang🇹🇼Taipei Medical University
- Yi-Ju Chiang🇹🇼China Medical University; China Medical University Hospital
- Hui-Ting Chen🇹🇼China Medical University; China Medical University Hospital
- Carmine Maria Pariante🇬🇧King's College London
Resumen
El texto original del estudio, en el idioma en que se publicó.
No studies have examined the relationship between endogenous polyunsaturated fatty acids (PUFAs) levels and treatment response to PUFAs. We conducted a 12-week, double-blind, placebo-controlled trial comparing the effects of high-dose eicosapentaenoic acid (EPA, 1.2 g) and placebo on cognitive function (continuous performance test) in n = 92 youth (age 6-18-years-old) with Attention Deficit Hyperactivity Disorder (ADHD). Blood erythrocytes PUFAs were measured before and after treatment, to examine the effects of baseline endogenous EPA levels on treatment response and the effects of EPA treatment on PUFAs levels. Secondary measures included other ADHD symptoms, emotional symptoms, and levels of plasma high-sensitivity c-reactive protein (hs-CRP) and brain-derived neurotrophic factor (BDNF). Overall, EPA group improved more than placebo group on focused attention (variability, Effect size (ES) = 0.38, p = 0.041); moreover, within youth with the lowest baseline endogenous EPA levels, EPA group improved more than placebo group in another measure of focused attention (hit reaction time, HRT, ES = 0.89, p = 0.015) and in vigilance (HRT interstimulus interval changes, HRTISIC, ES = 0.83, p = 0.036). Interestingly, EPA group improved less than placebo group in impulsivity (commission errors), both overall and in youth with the highest baseline EPA levels, who also showed less improvement in other ADHD and emotional symptoms. EPA increased blood erythrocytes EPA by 1.6-fold but not DHA levels, and did not affect hs-CRP and BDNF plasma levels. In conclusion, EPA treatment improves cognitive symptoms in ADHD youth, especially if they have a low baseline endogenous EPA level, while youth with high EPA levels may be negatively affected by this treatment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.